menu
    • menu
    [{"orgOrder":0,"company":"Respivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Cromoglicate","moa":"Mast Cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Respivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Respivant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Sodium Cromoglicate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Lupin Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals for Sodium Cromoglicate

    Menu

    Sodium Cromoglicate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sodium Cromoglicate,Bronchodil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lupin Atlantis Holdings completes acquisition of two brands from Sanofi in Europe & Canada

                            Details : Lupin has completed the acquisition of two well-known brands, Aarane (sodium cromoglicate) in Germany and Nalcrom (cromoglicic acid) in Canada and the Netherlands, from Sanofi.

                            Brand Name : Aarane

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 05, 2024

                            Lead Product(s) : Sodium Cromoglicate,Bronchodil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Respivant Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Respivant Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Cromoglicate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Respivant Sciences Supports International Rare Disease Day Through Awareness Activities

                            Details : Respivant also announces 50% enrollment milestone achieved in SCENIC, a Phase 2b Trial of RVT-1601 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 28, 2020

                            Lead Product(s) : Sodium Cromoglicate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth